

No.: 16600

Client No.:

Re No.: 16051-10US

**OGILVY
RENAULT**

LLP / S.E.N.C.R.L. s.r.l.

Facsimile**RECEIVED
CENTRAL FAX CENTER****APR 24 2006****Confidentiality Message**

This communication sent by facsimile is confidential, may be privileged and is intended for the exclusive use of the addressee. Any other person is strictly prohibited from disclosing, distributing or reproducing it. If the addressee cannot be reached or is unknown to you, please destroy this message and all copies. Thank you.

Number of pages including this cover sheet: 10
Date: April 24, 2006
From: Christian Cawthorn / Sarah Daigneault
Our File No. 16051-10US
Telephone: (514) 847-4256
Direct Fax: (514) 288-8389
E-Mail: ccawthorn@ogilvyrenault.com

(Appuyer sur Tab pour naviguer d'une cellule à l'autre ou ajouter une ligne à la fin du tableau))

To	Company - City	Fax
Commissioner of Patents	U.S. Patent & Trademark Office	1-571-273-8300

Message

Response to Office Action
Due April 24, 2006

Applicants: Andrew VAILLANT et al.
Serial Number: 10/661,355
Filing date: September 12, 2003
For: METHOD FOR IDENTIFYING ANTIVIRAL OLIGONUCLEOTIDES
Art Unit: 1648
Examiner: Sharon L. HURT

Barristers & Solicitors,
Patent Agents & Trade-mark Agents

Suite 1600
1981 McGill College Avenue
Montréal, Québec H3A 2Y3
Canada

Telephone (514) 847-4747
Fax (514) 288-8389

ogilvyrenault.com

RECEIVED
CENTRAL FAX CENTER

File No. 16051-10US CC/sd

APR 24 2006

April 24, 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Andrew VAILLANT et al.
Serial Number: 10/661,355
Filing date: September 12, 2003
For: METHOD FOR IDENTIFYING ANTIVIRAL OLIGONUCLEOTIDES
Art Unit: 1648
Examiner: Sharon L. HURT
Agent: Cawthorn, Christian (514) 847-4256

RESPONSE TO OFFICE ACTION

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia
22313-1450

Sir:

In response to the Office Action dated January 24, 2006, in connection with the above-identified patent application, please consider the following amendment and remarks.

AMENDMENTS TO THE SPECIFICATION

Amendments to the Specification begin on page 2 of this paper.

AMENDMENTS TO THE CLAIMS

Amendments to the claims are reflected in the listing of claims which begins on page 3 of this paper.

REMARKS

Remarks begin on page 7 of this paper.